OKYO Pharma Bolsters Cash Position with $25M Raise, Accelerates Phase 3 Trial
Event summary
- OKYO Pharma filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026.
- Raised approximately $25 million in capital, including a $22 million public offering in February 2026.
- Cash position strengthened to $20.6 million as of March 31, 2026, enabling completion of Phase 3 NEPTUNE trial.
- NEPTUNE Phase 3 trial planned for initiation in the second half of 2026, enrolling approximately 111 patients.
The big picture
OKYO Pharma's recent capital raise and strengthened cash position reflect a strategic pivot towards accelerating its lead candidate, urcosimod, through pivotal Phase 3 trials. This move aligns with broader trends in the biopharmaceutical sector where financial robustness is critical for navigating regulatory pathways and achieving market approval. The company's focus on neuropathic corneal pain addresses a significant unmet medical need, positioning it within a niche but growing segment of anterior segment eye diseases.
What we're watching
- Trial Execution
- The pace at which OKYO Pharma initiates and completes the NEPTUNE Phase 3 trial will determine its path to potential registration.
- Financial Runway
- Whether the $20.6 million cash position is sufficient to cover all operational costs until potential approval milestones are achieved.
- Regulatory Dynamics
- How FDA feedback and global trial design will influence the efficiency of the single-trial approval pathway for urcosimod.
Related topics